STENTOPLASTY WITH BIORESORBABLE BONE CEMENT FOR VERTEBRAL BODY FRACTURE

Objectives. To perform assessment of vertebral body mechanical properties after stentoplasty with bioresorbable bone cement in comparison with isolated use of polymethylmethacrylate (PPMA) and bioresorbable cement for vertebroplasty in experimental human cadaveric vertebral body.

Material and Methods. Twelve intact osteoporotic vertebrae from the cadaveric thoracolumbar spine (Th12, L1) were tested. They were subjected to X-ray investigation to exclude injury. Densitometry results confirmed the decreased mineral density of selected vertebrae. The mechanical compression of specimens was performed to simulate a wedge compression fracture of vertebral body.

Results. The mean compression strength of intact vertebrae was 3.2 MPa, that of vertebrae after vertebroplasty with PMMA – 8.8 MPa, after vertebroplasty with osteoconductive cement – 3.0 MPa, and after stentoplasty with osteoconductive cement – 3.6 MPa.

Conclusion. Vertebral body stenting with bioresorbable osteoconductive cement improved mechanical properties of fractured vertebrae as compared with intact vertebrae and those augmented only with bioresorbable cement. The obtained data on mechanical properties of vertebral specimens do not preclude a possible clinical application of stentoplasty with bioresorbable cement for vertebral body fractures.

1. Сикилинда В.Д., Акопов В.И., Хлопонин П.А. и др. Подготовка тканей экспериментальных животных и человека для биомеханических и морфологических исследований. Ростов н/Д, СПб., 2002.

2. Aebli N, Krebs J, Davis G, et al. Fat embolism and acute hypotension during vertebroplasty: an experimental study in sheep. Spine. 2002; 27: 460–466.

3. Alvarez L, Alcaraz M, Perez-Higueras A, et al. Percutaneous vertebroplasty: functional improvement in patients with osteoporotic compression fractures. Spine. 2006; 31: 1113–1118.

4. Bai B, Jazrawi LM, Kummer FJ, et al. The use of an injectable, biodegradable calcium phosphate bone substitute for the prophylactic augmentation of osteoporotic vertebrae and the management of vertebral compression fractures. Spine. 1999; 24: 1521–1526.

5. Bai B, Yin Z, Xu Q, et al. Histological changes of an injectable rhBMP-2/calcium phosphate cement in vertebroplasty of rhesus monkey. Spine. 2009; 34: 1887–1892.

6. Barnes B, Boden SD, Louis-Ugbo J, et al. Lower dose of rhBMP-2 achieves spine fusion when combined with an osteoconductive bulking agent in nonhuman primates. Spine. 2005; 30: 1127–1133.

7. Barralet JE, Grover LM, Gbureck U. Ionic modification of calcium phosphate cement viscosity. Part II: hypodermic injection and strength improvement of brushite cement. Biomaterials. 2004; 25: 2197–2203.

8. Beruto DT, Mezzasalma SA, Capurro M, et al. Use of alpha-tricalcium phosphate (TCP) as powders and as an aqueous dispersion to modify processing, microstructure, and mechanical properties of polymethylmethacrylate (PMMA) bone cements and to produce bone-substitute compounds. J Biomed Mater Res. 2000; 49: 498–505.

9. Boger A, Heini P, Windolf M, et al. Adjacent vertebral failure after vertebroplasty: a biomechanical study of low-modulus PMMA cement. Eur Spine J. 2007; 16: 2118–2125.

10. Breed AL. Experimental production of vascular hypotension, and bone marrow and fat embolism with methylmethacrylate cement. Traumatic hypertension of bone. Clin Orthop Relat Res. 1974; (102): 227–244.

11. Chow LC. Development of self-setting calcium phosphate cements: biomaterials. J Ceram Soc Japan. 1991; 99: 954–964.

12. Deramond H, Wright NT, Belkoff SM. Temperature elevation caused by bone cement polymerization during vertebroplasty. Bone. 1999; 25: 17S–21S.

13. Duran C, Sirvanci M, Aydogan M, et al. Pulmonary cement embolism: a complication of percutaneous vertebroplasty. Acta Radiol. 2007; 48: 854–859.

14. Felsenberg D, Silman AJ, Lunt M, et al. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res. 2002; 17: 716–724.

15. Feltes C, Fountas KN, Machinis T, et al. Immediate and early postoperative pain relief after kyphoplasty without significant restoration of vertebral body height in acute osteoporotic vertebral fractures. Neurosurg Focus. 2005; 18: e5.

16. Frankel BM, Monroe T, Wang C. Percutaneous vertebral augmentation: an elevation in adjacent-level fracture risk in kyphoplasty as compared with vertebroplasty. Spine J. 2007; 7: 575–582.

17. Galibert P, Deramond H, Rosat P, et al. [Preliminary note on the treatment of vertebral angioma by percutaneous acrylic vertebroplasty]. Neurochirurgie. 1987; 33: 166–168. In French.

18. Gold DT. The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone. 1996; 18: 185S–189S.

19. Heini PF, Orler R. [Vertebroplasty in severe osteoporosis. Technique and experience with multi-segment injection]. Orthopade. 2004; 33: 22–30. In German.

20. Hillmeier J, Grafe I, Da Fonseca K, et al. The evaluation of balloon kyphoplasty for osteoporotic vertebral fractures. An interdisciplinary concept. Orthopade. 2004; 33: 893–904.

21. Huang MH, Barrett-Connor E, Greendale GA, et al. Hyperkyphotic posture and risk of future osteoporotic fractures: the Rancho Bernardo study. J Bone Miner Res. 2006; 21: 419–423.

22. Iooss P, Le Ray AM, Grimandi G, et al. A new injectable bone substitute combining poly (epsilon-caprolactone) microparticles with biphasic calcium phosphate granules. Biomaterials. 2001; 22: 2785–2794.

23. Kado DM, Browner WS, Palermo L, et al. Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med. 1999; 159: 1215–1220.

24. Kanis JA, Melton LJ 3rd, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994; 9: 1137–1141.

25. Keaveny TM, Hayes WC. A 20-year perspective on the mechanical properties of trabecular bone. J Biomech Eng. 1993; 115: 534–542.

26. Keller T, Kosmopoulos V, Liebschner M. Modelling of bone damage and fracture in osteoporosis. In: Spalzki M, Gunzburg R, eds. Vertebral Osteoporotic Compression Fractures. Philadelphia; L., 2003: 35–50.

27. Ledlie JT, Renfro MB. Kyphoplasty treatment of vertebral fractures: 2-year outcomes show sustained benefits. Spine. 2006; 31: 57–64.

28. Liliang PC, Lu K, Liang CL, et al. Dyspnoea and chest pain associated with pulmonary polymethylmethacrylate embolism after percutaneous vertebroplasty. Injury. 2007; 38: 245–248.

29. McCalden RW, McGeough JA, Court-Brown CM. Age-related changes in the compressive strength of cancellous bone. The relative importance of changes in density and trabecular architecture. J Bone Joint Surg Am. 1997; 79: 421–427.

30. Peebles DJ, Ellis RH, Stride SD, et al. Cardiovascular effects of methylmethacrylate cement. Br Med J. 1972; 1: 349–351.

31. Seeherman H, Li R, Bouxsein M, et al. rhBMP-2/calcium phosphate matrix accelerates osteotomy-site healing in a nonhuman primate model at multiple treatment times and concentrations. J Bone Joint Surg Am. 2006; 88: 144–160.

32. Seeherman HJ, Azari K, Bidic S, et al. rhBMP-2 delivered in a calcium phosphate cement accelerates bridging of critical-sized defects in rabbit radii. J Bone Joint Surg Am. 2006; 88: 1553–1565.

33. Voggenreiter G. Balloon kyphoplasty is effective in deformity correction of osteoporotic vertebral compression fractures. Spine. 2005; 30: 2806–2812.